Search

Your search keyword '"Lluis Ballell"' showing total 89 results

Search Constraints

Start Over You searched for: Author "Lluis Ballell" Remove constraint Author: "Lluis Ballell"
89 results on '"Lluis Ballell"'

Search Results

1. Novel inhibitors that target bacterial virulence identified via HTS against intra-macrophage survival of Shigella flexneri

2. Tyrosine Kinase Inhibitors Display Potent Activity against Cryptosporidium parvum

Catalog

Books, media, physical & digital resources

3. Correction: The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant Shigella spp

4. The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant Shigella spp

5. Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening

6. An open toolkit for tracking open science partnership implementation and impact [version 2; peer review: 2 approved]

7. Identification of KasA as the cellular target of an anti-tubercular scaffold

8. Antitubercular drugs for an old target: GSK693 as a promising InhA direct inhibitor

9. Target Identification of Mycobacterium tuberculosis Phenotypic Hits Using a Concerted Chemogenomic, Biophysical, and Structural Approach

10. Encapsulation of Anti-Tuberculosis Drugs within Mesoporous Silica and Intracellular Antibacterial Activities

11. Correction: Author Correction: Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening

12. Mycobacterial dihydrofolate reductase inhibitors identified using chemogenomic methods and in vitro validation.

13. Biochemical and structural characterization of mycobacterial aspartyl-tRNA synthetase AspS, a promising TB drug target.

14. Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB.

15. Tebipenem as an oral alternative for the treatment of typhoid caused by XDR Salmonella Typhi

16. Correction: The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant Shigella spp

17. The small-molecule SMARt751 reverses Mycobacterium tuberculosis resistance to ethionamide in acute and chronic mouse models of tuberculosis

18. Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-<scp>d</scp>-Ribose Oxidase (DprE1) Inhibitors

19. MymA Bioactivated Thioalkylbenzoxazole Prodrug Family Active against Mycobacterium tuberculosis

20. Author response: The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug-resistant Shigella spp

21. Novel Pyrazole-Containing Compounds Active against Mycobacterium tuberculosis

22. Repurposing Infectious Disease Hits as Anti-Cryptosporidium Leads

23. Fighting

24. Repurposing Infectious Disease Hits as Anti

25. Tres Cantos Open Lab: celebrating a decade of innovation in collaboration to combat endemic infectious diseases

26. MymA Bioactivated Thioalkylbenzoxazole Prodrug Family Active against

27. Identification and Profiling of Hydantoins—A Novel Class of Potent Antimycobacterial DprE1 Inhibitors

28. Synthesis, antimycobacterial activity and influence on mycobacterial InhA and PknB of 12-membered cyclodepsipeptides

29. In vivo potent BM635 analogue with improved drug-like properties

30. Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis

31. A new piperidinol derivative targeting mycolic acid transport inMycobacterium abscessus

32. An open toolkit for tracking open science partnership implementation and impact

33. Correction: Author Correction: Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening

34. The antibiotic cyclomarin blocks arginine-phosphate-induced millisecond dynamics in the N-terminal domain of ClpC1 from

35. Whole Cell Target Engagement Identifies Novel Inhibitors of Mycobacterium tuberculosis Decaprenylphosphoryl-β-<scp>d</scp>-ribose Oxidase

36. A Focused Screen Identifies Antifolates with Activity on Mycobacterium tuberculosis

37. Mycobacterium tuberculosis Gyrase Inhibitors as a New Class of Antitubercular Drugs

38. Rapid Cytolysis of Mycobacterium tuberculosis by Faropenem, an Orally Bioavailable β-Lactam Antibiotic

39. Accelerating Early Antituberculosis Drug Discovery by Creating Mycobacterial Indicator Strains That Predict Mode of Action

40. A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors

41. Encapsulation of Anti-Tuberculosis Drugs within Mesoporous Silica and Intracellular Antibacterial Activities

42. An open toolkit for tracking open science partnership implementation and impact

43. Combinations of β-Lactam Antibiotics Currently in Clinical Trials Are Efficacious in a DHP-I-Deficient Mouse Model of Tuberculosis Infection

44. Discovery of novel InhA reductase inhibitors: application of pharmacophore- and shape-based screening approach

45. Pharmaceutical salt of BM635 with improved bioavailability

46. In vivo oral toxicological evaluation of mesoporous silica particles

47. Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening

48. Repurposing clinically approved cephalosporins for tuberculosis therapy

49. A new piperidinol derivative targeting mycolic acid transport in Mycobacterium abscessus

50. 4-Substituted Thioquinolines and Thiazoloquinolines: Potent, Selective, and Tween-80 in vitro Dependent Families of Antitubercular Agents with Moderate in vivo Activity